Compare UNH & JNJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UNH | JNJ |
|---|---|---|
| Founded | 1977 | 1886 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 360.3B | 542.4B |
| IPO Year | 2010 | 2003 |
| Metric | UNH | JNJ |
|---|---|---|
| Price | $417.43 | $263.90 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 26 | 23 |
| Target Price | ★ $477.04 | $279.41 |
| AVG Volume (30 Days) | 5.1M | ★ 6.6M |
| Earning Date | 10-13-2026 | 10-13-2026 |
| Dividend Yield | ★ 2.18% | 2.00% |
| EPS Growth | N/A | ★ 90.50 |
| EPS | ★ 12.94 | 4.49 |
| Revenue | ★ $447,567,000,000.00 | N/A |
| Revenue This Year | $0.16 | $7.46 |
| Revenue Next Year | $3.37 | $6.60 |
| P/E Ratio | ★ $32.80 | $59.73 |
| Revenue Growth | ★ 11.81 | N/A |
| 52 Week Low | $255.97 | $184.66 |
| 52 Week High | $461.62 | $281.07 |
| Indicator | UNH | JNJ |
|---|---|---|
| Relative Strength Index (RSI) | 65.22 | 53.03 |
| Support Level | $414.37 | $262.26 |
| Resistance Level | $461.62 | $266.91 |
| Average True Range (ATR) | 12.14 | 5.81 |
| MACD | 5.01 | 1.14 |
| Stochastic Oscillator | 84.19 | 76.08 |
UnitedHealth Group is one of the largest private health insurers and provides medical benefits to about 51 million members globally, including 1 million outside the US as of December 2025. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in medical insurance. Along with its insurance assets, UnitedHealth's Optum franchises help create a healthcare services colossus that spans everything from pharmaceutical benefits to providing outpatient care and analytics to affiliates and third parties.
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.